PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 17459442-2 2007 While it has been proposed that this reduction is due to deamination of deoxycytidine in viral DNA by either hA3G or hA3F, followed by DNA degradation, recent evidence indicates that the inhibition of viral DNA production can occur independently of DNA editing by either hA3F or hA3G. Deoxycytidine 72-85 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 109-113 28066353-1 2016 APOBEC3G (A3G) is a member of the cellular polynucleotide cytidine deaminases, which catalyze the deamination of cytosine (dC) to uracil (dU) in single-stranded DNA. Deoxycytidine 123-125 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 0-8 28066353-1 2016 APOBEC3G (A3G) is a member of the cellular polynucleotide cytidine deaminases, which catalyze the deamination of cytosine (dC) to uracil (dU) in single-stranded DNA. Deoxycytidine 123-125 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 10-13 21737457-1 2011 APOBEC3G (A3G) is a cytidine deaminase that catalyzes deamination of deoxycytidine (dC) on single-stranded DNA (ssDNA). Deoxycytidine 69-82 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 0-8 21737457-1 2011 APOBEC3G (A3G) is a cytidine deaminase that catalyzes deamination of deoxycytidine (dC) on single-stranded DNA (ssDNA). Deoxycytidine 69-82 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 10-13 21737457-1 2011 APOBEC3G (A3G) is a cytidine deaminase that catalyzes deamination of deoxycytidine (dC) on single-stranded DNA (ssDNA). Deoxycytidine 84-86 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 0-8 21737457-1 2011 APOBEC3G (A3G) is a cytidine deaminase that catalyzes deamination of deoxycytidine (dC) on single-stranded DNA (ssDNA). Deoxycytidine 84-86 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 10-13 20219919-2 2010 A3G is packaged into human immunodeficiency virus type 1 virions and deaminates deoxycytidine to deoxyuridine on nascent minus-strand retroviral cDNA, leading to hyper-deoxyguanine-to-deoxyadenine mutations on positive-strand cDNA and inhibition of viral replication. Deoxycytidine 80-93 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 0-3 19421154-0 2009 Mechanisms of APOBEC3G-catalyzed processive deamination of deoxycytidine on single-stranded DNA. Deoxycytidine 59-72 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 14-22 28928403-1 2017 APOBEC3G (A3G) is a human enzyme that inhibits human immunodeficiency virus type 1 (HIV-1) infectivity, in the absence of the viral infectivity factor Vif, through deoxycytidine deamination and a deamination-independent mechanism. Deoxycytidine 164-177 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 0-8 28928403-1 2017 APOBEC3G (A3G) is a human enzyme that inhibits human immunodeficiency virus type 1 (HIV-1) infectivity, in the absence of the viral infectivity factor Vif, through deoxycytidine deamination and a deamination-independent mechanism. Deoxycytidine 164-177 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 10-13 21300806-0 2011 Intensity of deoxycytidine deamination of HIV-1 proviral DNA by the retroviral restriction factor APOBEC3G is mediated by the noncatalytic domain. Deoxycytidine 13-26 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 98-106 18036235-3 2007 During the post entry phase of infection, hA3G attenuates viral replication by binding to the viral RNA genome and deaminating deoxycytidines to form deoxyuridines within single stranded DNA regions of the replicated viral genome. Deoxycytidine 127-141 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 42-46 17459442-2 2007 While it has been proposed that this reduction is due to deamination of deoxycytidine in viral DNA by either hA3G or hA3F, followed by DNA degradation, recent evidence indicates that the inhibition of viral DNA production can occur independently of DNA editing by either hA3F or hA3G. Deoxycytidine 72-85 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 279-283 15571253-1 2004 UNLABELLED: Gemcitabine is a deoxycytidine analog, which can be inactivated by deamination catalyzed by deoxycytidine deaminase (dCDA). Deoxycytidine 29-42 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 104-127 17201059-2 2006 The human cytidine deaminase APOBEC3G, that catalyses the deoxycytidine to deoxyuridine deamination reaction in the reverse transcript of the HIV-1 genome, leads to instability of the viral DNA, if only HIV-1 virion is defective and lacks the Vif protein. Deoxycytidine 58-71 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 29-37 15829920-9 2005 Surprisingly, sequencing of the reverse transcripts slowly formed in unstimulated CD4+ T cells reveals only low levels of dG dA hypermutation, raising the possibility that the APOBEC3G-restricting activity may not be strictly dependent on deoxycytidine deamination Deoxycytidine 239-252 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 176-184 15054139-2 2004 Recently, the human apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3G (APOBEC3G), first identified as CEM15, was shown to be packaged into retroviral virions and to deaminate deoxycytidine to deoxyuridine in newly synthesized viral minus-strand DNA, thereby inducing G-to-A hypermutation. Deoxycytidine 194-207 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 20-88 15210704-2 2004 APOBEC3G deaminates deoxycytidines in minus strand DNA to deoxyuridines, resulting in G to A hypermutation and viral inactivation. Deoxycytidine 20-34 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 0-8 15054139-2 2004 Recently, the human apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3G (APOBEC3G), first identified as CEM15, was shown to be packaged into retroviral virions and to deaminate deoxycytidine to deoxyuridine in newly synthesized viral minus-strand DNA, thereby inducing G-to-A hypermutation. Deoxycytidine 194-207 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 90-98 15054139-2 2004 Recently, the human apolipoprotein B mRNA-editing, enzyme-catalytic, polypeptide-like 3G (APOBEC3G), first identified as CEM15, was shown to be packaged into retroviral virions and to deaminate deoxycytidine to deoxyuridine in newly synthesized viral minus-strand DNA, thereby inducing G-to-A hypermutation. Deoxycytidine 194-207 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 121-126 31939152-2 2019 A3G is a zinc-dependent enzyme that mutates select deoxycytidines (dC) to deoxyuridine (dU) through deamination within nascent single stranded DNA (ssDNA) during HIV reverse transcription. Deoxycytidine 51-65 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 0-3 14528300-1 2003 The human protein apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like-3G (APOBEC3G), also known as CEM-15, mediates a newly described form of innate resistance to retroviral infection by catalyzing the deamination of deoxycytidine to deoxyuridine in viral cDNA replication intermediates. Deoxycytidine 229-242 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 18-84 14528300-1 2003 The human protein apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like-3G (APOBEC3G), also known as CEM-15, mediates a newly described form of innate resistance to retroviral infection by catalyzing the deamination of deoxycytidine to deoxyuridine in viral cDNA replication intermediates. Deoxycytidine 229-242 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 86-94 14528300-1 2003 The human protein apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like-3G (APOBEC3G), also known as CEM-15, mediates a newly described form of innate resistance to retroviral infection by catalyzing the deamination of deoxycytidine to deoxyuridine in viral cDNA replication intermediates. Deoxycytidine 229-242 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 111-117 31850845-1 2019 APOBEC3G (A3G), an enzyme expressed in primates with the potential to inhibit human immunodeficiency virus type 1 (HIV-1) infectivity, is a single-stranded DNA (ssDNA) deoxycytidine deaminase with two domains, a catalytically active, weakly ssDNA binding C-terminal domain (CTD) and a catalytically inactive, strongly ssDNA binding N-terminal domain (NTD). Deoxycytidine 168-181 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 0-8 31850845-1 2019 APOBEC3G (A3G), an enzyme expressed in primates with the potential to inhibit human immunodeficiency virus type 1 (HIV-1) infectivity, is a single-stranded DNA (ssDNA) deoxycytidine deaminase with two domains, a catalytically active, weakly ssDNA binding C-terminal domain (CTD) and a catalytically inactive, strongly ssDNA binding N-terminal domain (NTD). Deoxycytidine 168-181 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 10-13 31939152-2 2019 A3G is a zinc-dependent enzyme that mutates select deoxycytidines (dC) to deoxyuridine (dU) through deamination within nascent single stranded DNA (ssDNA) during HIV reverse transcription. Deoxycytidine 67-69 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 0-3 31939152-4 2019 Once inside infected cells, A3G must bind to nascent ssDNA reverse transcripts for dC to dU base modification gene editing. Deoxycytidine 83-85 apolipoprotein B mRNA editing enzyme catalytic subunit 3G Homo sapiens 28-31